Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Study results confirm T-SPOT.TB performance is not affected by low CD4 count in HIV infected subject

Press Release
At Oxford Immunotec:
Dr Peter Wrighton-Smith, CEO
Tel: +44 (0)1235 442780
Fax: +44 (0)1235 442781

Oxford Immunotec
94c Milton Park
Oxfordshire OX14 4RY, UK

Oxford Immunotec Inc,
2 Mount Royal Avenue,
MA 01752

Oxford, UK; 23 May 2008 – Oxford Immunotec, the T cell measurement company, today announced the publication of a recent study, demonstrating the efficacy of using T-SPOT.TB to identify TB infection in HIV infected subjects.

In this study reported in Clinical and Experimental Immunology Clark et al showed that the T-SPOT.TB test was unaffected by CD4 count, having the same high sensitivity in patients with a very low CD4 count (less than 100 cells/μl) as those with a more normal CD4 count (above 400 cells/μl).

In the publication the authors conclude that “T-SPOT.TB is a useful assay to screen for TB infection even in HIV-1 patients with low CD4 counts and can be used in routine clinical practice”.

Commenting on the results, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “this study confirms the role of T-SPOT.TB in the identification of TB infection in HIV infected subjects. This is particularly important as TB is one of the major causes of death in HIV infected subjects and the rates of TB/HIV co-infection are reaching epidemic proportions in some populations”.

– Ends –

Notes to editors:

About Oxford Immunotec
Oxford Immunotec, the T cell measurement company is based in Oxford, UK and Marlborough, MA. The Company develops and sells clinical diagnostic products based on its patented T-SPOT® technology, the first regulatory approved method for directly quantifying antigen-specific T cells.

T-SPOT is a simple and extremely accurate method of studying a person’s cellular immune response to infection and can be applied to diagnose and monitor any major disease driven by a T cell response.

About T-SPOT®.TB
T-SPOT.TB is an in vitro T cell measurement assay used for diagnosing TB disease and latent TB infection and the first product from Oxford Immunotec using the T-SPOT technology. The product is extremely robust in that it gives a result every time and offers unrivalled and maintained sensitivity in high risk and immunocompromised patient groups. T-SPOT.TB is approved for sale in Europe, Canada & over 40 other countries worldwide and is designed to replace the 115 year old Tuberculin Skin Test. As such it offers a substantially more accurate and effective tool for controlling the spread of TB, addressing a market opportunity exceeding $1bn.

T-SPOT® is a trademark of Oxford Immunotec.

Journal Reference

Clark S, Martin S, Pozniak A, Steel A, Ward B, Dunning J, Henderson D, Nelson M, Gazzard B and Kelleher P. Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease.
Clinical and Experimental Immunology. 1365-2249. 2007.

Publisher Contact Information:

Oxford Immunotec Ltd.
+44 (0)1235 442780

Company profile of Oxford Immunotec Ltd.
Past press releases of Oxford Immunotec Ltd..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jul 31€2.8MInternet services
Jul 30€9.5MWireless applications
Jul 30€4.5MSensors
Jul 30€5.0ME-Commerce
Jul 30N/ANetwork management
Jul 30€72.0MInternet services

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

Oct 1
The Link App
the link app launches version 2.0

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.